Tenapanor
- Generic Name
- Tenapanor
- Brand Names
- Ibsrela
- Drug Type
- Small Molecule
- Chemical Formula
- C50H66Cl4N8O10S2
- CAS Number
- 1234423-95-0
- Unique Ingredient Identifier
- WYD79216A6
- Background
Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transporter, it is the first and currently only medication within its class and therefore ex...
- Indication
Tenapanor is indicated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in adults.
...
- Associated Conditions
- Chronic Kidney Disease (CKD), Irritable Bowel Syndrome With Constipation (IBS-C)
- Associated Therapies
- -
4-Week, Multi-Center, Randomized, Db-Blind, Placebo-Controlled, Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 72
- Registration Number
- NCT06553547
- Locations
- 🇺🇸
Florida Pharmaceutical Research and Associates, Inc., South Miami, Florida, United States
A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT06481150
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Tenapanor in Synucleinopathy-Related Constipation
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Cedar Valley Digestive Health Center
- Target Recruit Count
- 30
- Registration Number
- NCT06460038
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 7
- Registration Number
- NCT06203444
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸DDSI, Oklahoma City, Oklahoma, United States
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Kyle Staller, MD, MPH
- Target Recruit Count
- 30
- Registration Number
- NCT05995899
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 150
- Registration Number
- NCT05905926
- Locations
- 🇺🇸
Advantage Clinical Trials, Bronx, New York, United States
🇺🇸Frontier Clinical Research, Kingwood, West Virginia, United States
🇺🇸G & L Research, LLC, Foley, Alabama, United States
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 333
- Registration Number
- NCT04549597
- Locations
- 🇺🇸
South Florida Research Institute, Lauderdale Lakes, Florida, United States
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
- Conditions
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 172
- Registration Number
- NCT03988920
- Locations
- 🇺🇸
Ardelyx Site #509, Houston, California, United States
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 236
- Registration Number
- NCT03824587
- Locations
- 🇺🇸
Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸Mountain Kidney & Hypertension Associates, P.A., Asheville, North Carolina, United States
🇺🇸California Institute of Renal Research - Chula Vista, Chula Vista, California, United States
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 1559
- Registration Number
- NCT03427125
- Locations
- 🇺🇸
Site 529, Bronx, New York, United States
🇺🇸Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.